Use access key #2 to skip to page content.

Closing XOMA (XOMA) underperform

Recs

1

May 06, 2008 – Comments (0) | RELATED TICKERS: XOMA

I don't think XOMA is going down to 1 any more, considering the stock has survived the vaporization of the Neuprex program and the complete absence of news on HCD-122. Future prospects related to antibody royalties are simply too difficult to predict for a retail investor given the complexity and opacity of the relationships with larger pharmaceutical companies. This forces me to rely on price momentum and analyst opinion, both of which seem favorable to XOMA at the present time.

0 Comments – Post Your Own

Featured Broker Partners


Advertisement